30 completed, 11 active not recruiting, 11 recruiting, 9 unknown. 75 Phase 2, 42 Phase 1, 6 Phase 3.
Follow Retinitis Pigmentosa: new trials by email Literature Review of Retinitis Pigmentosa trials Research Report on Retinitis Pigmentosa
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Long-Term Safety of Ultevursen in Participants With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene No intervention, will not receive any active study intervention, Intravitreal Injection of Ultevursen - Retinitis Pigmentosa (RP), Usher Syndrome Type 2 | Phase 2 | Not yet recruiting | Laboratoires Thea | 81 | 2026-10-05 | 2026-09-01 |
| Study to Evaluate the Efficacy of a Single Intravitreal Injection of RTx-015 in Participants With Retinitis Pigmentosa (PERCEPT) RTx-015, Sham Control - Retinitis Pigmentosa (RP), Inherited Retinal Diseases | Phase 2 / Phase 3 | Recruiting | Ray Therapeutics, Inc. | 60 | 2026-10-01 | 2026-10-28 |
| 9-cis Beta-Carotene-Rich Extract of Dunaliella Alga in Retinitis Pigmentosa Patients 9-cis beta-Carotene-rich extract of Dunaliella alga, Placebo Corn Oil - Retinitis Pigmentosa | Phase 1 / Phase 2 | Enrolling by invitation | Sheba Medical Center | 41 | 2026-07-26 | 2026-07-27 |
| Prospective, Randomized, Sham-controlled, Dose-finding I/II Trial of Safety and Efficacy of Modified Optogenetic Gene Therapy (ZM-02 Injection) ZM-02 (low dose), ZM-02 (high dose), ZM-02 (selected dose) - Retinitis Pigmentosa (RP) | Phase 1 / Phase 2 | Not yet recruiting | Zhongmou Therapeutics | 21 | 2026-06-25 | 2026-04-13 |
| Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II 1.5 x 10^6 UC-MSC + CM, 5 x 10^6 UC-MSC + CM - Retinitis Pigmentosa | Phase 2 / Phase 3 | Not yet recruiting | PT. Prodia Stem Cell Indonesia | 30 | 2026-05-01 | 2026-02-25 |
| A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa DSP-3077 Retinal Sheet Cohort 1, DSP-3077 Retinal Sheet Cohort 2, DSP-3077 Retinal Sheet Cohort 3 - Retinitis Pigmentosa | Phase 1 / Phase 2 | Recruiting | Sumitomo Pharma America, Inc. | 12 | 2026-04-16 | 2026-04-17 |
| A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP) Phase 1b/2: Cohort 1 - OCT-980 Tablet, Phase 1b/2: Cohort 2 - OCT-980 Tablet, Phase 1b/2: Cohort 3 - OCT-980 Tablet - Retinitis Pigmentosa | Phase 1 / Phase 2 | Recruiting | Octant, Inc. | 18 | 2026-03-10 | 2026-09-24 |
| The Effect of Oral Administration of 9-cis Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Adolescent Patients With Retinitis Pigmentosa Alga Dunaliella Bardawil powder, Placebo:Starch - Retinitis Pigmentosa | Phase 1 / Phase 2 | Not yet recruiting | Sheba Medical Center | 30 | 2026-03-01 | 2025-10-06 |
| Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Gene Therapy (SPVN20) in Subjects With Rod-Cone Dystrophy SPVN20 (high dose), SPVN20 (medium dose), SPVN20 (low dose) - Retinitis Pigmentosa (RP), Rod Cone Dystrophy | Phase 1 / Phase 2 | Recruiting | SparingVision | 27 | 2025-10-08 | 2026-09-08 |
| A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa Placebo (Sterile Saline or Balanced Salt Solution), 100 μg KIO-301, 50 μg KIO-301 - Retinitis Pigmentosa | Phase 2 | Recruiting | Kiora Pharmaceuticals, Inc. | 36 | 2025-08-29 | 2026-06-18 |
| Safety and Efficacy of ZVS203e in the Treatment of Retinitis Pigmentosa Caused by RHO Gene Mutation ZVS203e - Retinitis Pigmentosa | Phase 1 / Phase 2 | Recruiting | Chigenovo Co., Ltd | 18 | 2025-08-04 | 2026-06-17 |
| Intravitreal Adalimumab in Inherited and Degenerative Retinal Diseases Intravitreal Adalimumab - Retinitis Pigmentosa (RP), Extensive Macular Atrophy With Pseudodrusen (EMAP) | Phase 1 / Phase 2 | Active not recruiting | Centro de Pesquisa Rubens Siqueira | 30 | 2025-07-10 | 2026-10-27 |
| Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP) human retinal progenitor cells, Mock injection - Retinitis Pigmentosa | Phase 2 | Active not recruiting | jCyte, Inc | 31 | 2025-06-20 | 2026-07-30 |
| A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO) OpCT-001 - Primary Photoreceptor Disease, Retinitis Pigmentosa (RP) | Phase 1 / Phase 2 | Recruiting | BlueRock Therapeutics | 54 | 2025-03-10 | 2026-10-15 |
| Subtenon Autologous Platelet-Rich Plasma in Inherited and Degenerative Retinal Diseases Subtenon Injection of Autologous Platelet-Rich Plasma - Extensive Macular Atrophy With Pseudodrusen (EMAP), Retinitis Pigmentosa (RP) | Phase 1 / Phase 2 | Active not recruiting | Rubens Camargo Siqueira | 30 | 2025-01-04 | 2026-07-01 |
| Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene Intravitreal Injection of Ultevursen, No intervention, will not receive any active study intervention - Retinitis Pigmentosa (RP), Usher Syndrome Type 2 | Phase 2 | Active not recruiting | Laboratoires Thea | 81 | 2024-12-11 | 2026-07-09 |
| Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies ACE Retino - Retinitis Pigmentosa (RP), Age Related Macular Degeneration | Phase 1 / Phase 2 | Recruiting | Ace Cells Lab Limited | 100 | 2024-11-12 | 2025-04-25 |
| Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa AAVB-081 - Usher Syndrome, Type 1B | Phase 1 / Phase 2 | Recruiting | AAVantgarde Bio Srl | 15 | 2024-07-02 | 2025-05-02 |
| Safety and Efficacy of Stem Cell Small Extracellular Vesicles in Patients With Retinitis Pigmentosa GMP compliant-BM-MSC derived sEVs - Retinitis Pigmentosa | Phase 1 / Phase 2 | Recruiting | Mahidol University | 15 | 2024-05-23 | 2025-05-15 |
| Promising ROd-cone DYstrophy Gene therapY SPVN06 - Retinitis Pigmentosa | Phase 1 / Phase 2 | Active not recruiting | SparingVision | 33 | 2023-04-12 | 2026-05-15 |
Showing 20 of 75. Sign in to see all of them.
Retinal Diseases (16) · Eye Diseases (15) · Usher Syndromes (12) · Eye Diseases, Hereditary (10) · Retinal Degeneration (9) · Vision Disorders (9) · Cone-Rod Dystrophies (6) · Eye Abnormalities (5) · Retinal Dystrophies (5) · Macular Edema (4) · Choroideremia (2) · Macular Degeneration (2) · Night Blindness, Congenital Stationary, Autosomal Dominant 1 (2) · Retinitis (2)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (75) · Genetic Diseases, Inborn (74) · Retinal Dystrophies (68) · Eye Diseases, Hereditary (65) · Retinal Degeneration (64) · Eye Diseases (60) · Retinal Diseases (57) · Nervous System Diseases (17) · Neurologic Manifestations (16) · Pathological Conditions, Signs and Symptoms (16) · Sensation Disorders (16) · Signs and Symptoms (16) · Abnormalities, Multiple (14) · Congenital Abnormalities (14) · Blindness (12)
Intravitreal Injections (4) · salicylhydroxamic acid (4) · Ciliary Neurotrophic Factor (3) · Minocycline (2) · Ophthalmic Solutions (2) · Valproic Acid (2) · cenegermin (2) · Blood Specimen Collection (1) · Brimonidine Tartrate (1) · Culture Media, Conditioned (1) · Docosahexaenoic Acids (1) · Electroconvulsive Therapy (1) · Fatty Acids, Omega-3 (1) · Genetic Therapy (1) · Hydroxychloroquine (1)
Laboratoires Thea (5) · jCyte, Inc (4) · Neurotech Pharmaceuticals (3) · Sheba Medical Center (3) · Kiora Pharmaceuticals, Inc. (2) · Nanoscope Therapeutics Inc. (2) · PT. Prodia Stem Cell Indonesia (2) · ProQR Therapeutics (2) · Sanofi (2) · SparingVision (2) · AAVantgarde Bio Srl (1) · AbbVie (1) · Ace Cells Lab Limited (1) · Acibadem University (1) · Aldeyra Therapeutics, Inc. (1)
United States (36) · France (11) · United Kingdom (9) · Brazil (4) · Germany (4) · Italy (4) · Australia (3) · Canada (3) · Israel (3) · Belgium (2) · China (2) · India (2) · Indonesia (2) · Netherlands (2) · Turkey (Türkiye) (2)
David Liao, MD (2) · Mitul Mehta, MD (2) · Rubens C Siqueira, MD,PhD (2) · Ahmad Mansour, MD (1) · Andrew J Lotery, MD (1) · Andrew R Webster, MD (1) · Anthony Joseph, MD (1) · Anthony Jospeh, MD (1) · Baruch Kuppermann, MD (1)
PMID 23049090, PMID 23668681, PMID 32573764, PMID 10511047, PMID 11931789, PMID 15302656, PMID 16759390, PMID 21087953, PMID 22828504, PMID 23828615, PMID 24439297, PMID 24705452, PMID 24805262, PMID 25015354, PMID 25342618, PMID 25744334, PMID 26469750, PMID 26857842, PMID 27403996, PMID 27820636, PMID 29879277, PMID 30218651, PMID 30646425, PMID 31215818, PMID 32041720, PMID 36882562, PMID 37418643, PMID 39256350, PMID 39627217, PMID 39878701, PMID 40339601, PMID 40759732, PMID 40927136, PMID 41769936, PMID 41981307, PMID 42193355, PMID 42842903
2016 (2), 2009 (1), 2015 (1), 2017 (1), 2018 (1), 2025 (1)